Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Open Label Study of Daratumumab in Relapsed or Refractory Non-Hodgkin Lymphoma
2014-005299-26Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- May 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of daratumumab in mantle cell lymphoma (MCL), diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), sponsored by Janssen Pharmaceutical. Started May 2015; status: completed.
02
Drugs
daratumumab
03
Conditions
mantle cell lymphoma (MCL)diffuse large B-cell lymphoma (DLBCL)follicular lymphoma (FL)
Beyond the preview
Go deeper on 2014-005299-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-005299-26.